What led Dendreon, the company that pioneered a drug many considered the next big thing in cancer research, to file for bankruptcy?
Is there a lesson to be learned from Dendreon's bankruptcy protection filing? CNBC contributor Herb Greenberg, provides perspective on the risks associated with passive investing.
Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.
Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.
Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.
--Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.
--Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.